Han Kun has advised and acted as the PRC counsel and the PRC data compliance advisor to METiS TechBio Co., Ltd. (剂泰科技（北京）股份有限公司) ("METiS TechBio", Stock Code: 7666.HK) in connection with its IPO and listing of H shares on the Main Board of the Stock Exchange of Hong Kong Limited, assisting Metis TechBio in becoming the world's first publicly listed AI drug delivery company and the first AI macromolecular biopharmaceuticals company listed on the Hong Kong Stock Exchange.
METiS TechBio has independently developed the world's first AI-driven nanodelivery platform, built the world's largest 10-million-scale ionizable lipid library, independently created the world's only de novo lipid generation algorithm and lipid language model, established the world's first end-to-end lipid and lipid nanoparticle (LNP) screening platform, and pioneered the world's first AI + multi-dimensional simulation small molecule formulation platform. METiS TechBio has more than 10 pipeline products, including MTS-004, the first AI-enabled formulation new drug in China to complete Phase III clinical trials, bringing hope to fill the domestic treatment gap for Pseudobulbar Affect (PBA).
